Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2351

Sort by

Sort Order Select

Journal Articles

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Rami Komrokji, Virginia Volpe, Onyee Chan, Najla Al Ali, David Swoboda, Andrew Kuykendall, Eric Padron, David A. Sallman

Blood (2021) 138 (11): 989–992.

https://doi.org/10.1182/blood.2021010831

Published: 2021

Journal Articles

All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML

Yin Yuan, Stephen Boyle

Blood (2021) 137 (23): 3310.

https://doi.org/10.1182/blood.2021011357

Published: 2021

Journal Articles

A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment

Chloé Friedrich, Sylvain Barreau

Blood (2020) 136 (1): 148.

https://doi.org/10.1182/blood.2020005728

Published: 2020

Journal Articles

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Chong Chyn Chua, MBBS, John Reynolds, PhD, Jessica M Salmon, PhD, Chun Fong, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Ing Soo Tiong, MBBS,FRACP,FRCPA, Shaun Fleming, MBBS,, Sarah MacRaild, Donia M Moujalled, PhD, Giovanna Pomilio, Nik Cummings, Julie McManus, Adam Ivey, BSc, MSc, PhD, Purvi M Kakadia, PhD, Stefan K. Bohlander, MD, Andrew W. Roberts, MBBS, PhD FRACP, FRCPA, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 462.

https://doi.org/10.1182/blood-2019-126640

Published: 2019

Journal Articles

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 570.

https://doi.org/10.1182/blood-2019-128178

Published: 2019

Journal Articles

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Gautam M. Borthakur, MD, Olatoyosi Odenike, MD, Ibrahim Aldoss, MD, David A. Rizzieri, MD, Thomas Prebet, MD PhD, Dimple A. Modi, PhD, Rujuta Joshi, Beibei Hu, Yan Sun, PhD, Johannes E. Wolff, MD, Brian A Jonas, MD PhD

Blood (2019) 134 (Supplement_1): 539.

https://doi.org/10.1182/blood-2019-126854

Published: 2019

Journal Articles

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Blood (2019) 134 (Supplement_1): 666.

https://doi.org/10.1182/blood-2019-127127

Published: 2019

Journal Articles

Acute Myeloid Leukemia (AML) in a 3D Bone Marrow Niche Showed High Performance for in Vitro and In Vivo Drug Screenings

Giulia Borella, Ambra Da Ros, Elena Porcù, PhD, Claudia Tregnago, PhD, Maddalena Benetton, Valeria Bisio, PhD, Elisabetta Campodoni, Silvia Panseri, PhD, Monica Sandri, PhD, Monica Montesi, PhD, Stefano Cairo, PhD, Franco Locatelli, MD PhD, Martina Pigazzi, PhD

Blood (2019) 134 (Supplement_1): 544.

https://doi.org/10.1182/blood-2019-128382

Published: 2019

Journal Articles

Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy

Guillermo Montalban-Bravo, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Courtney D. DiNardo, MD MSc, Elias Jabbour, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD

Blood (2019) 134 (Supplement_1): 647.

https://doi.org/10.1182/blood-2019-129373

Published: 2019

Journal Articles

Transient Switch to Myeloid Lineage in Acute Lymphoblastic Leukemia during Induction Therapy: The Role of CD371 Expression and Implication for Minimal Residual Disease Detection

Elena Varotto, MD PhD, Margarita Maurer-Granofszky, PhD, Daniela Silvestri, Pamela Scarparo, PhD, Ester Mejstrikova, MD PhD, Monika Brüggemann, Giovanni Cazzaniga, PhD, Valentino Conter, MD, Ondrej Hrusak, MD PhD, Giuseppe Gaipa, PhD, Angela Schumich, Maria Grazia Valsecchi, PhD, Giuseppe Basso, MD PhD, Michael Dworzak, MD, Barbara Buldini, MD PhD

Blood (2019) 134 (Supplement_1): 377.

https://doi.org/10.1182/blood-2019-127287

Published: 2019

Journal Articles

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Blood (2019) 134 (Supplement_1): 226.

https://doi.org/10.1182/blood-2019-131086

Published: 2019

Journal Articles

Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia

Seth E Karol, MD, Thomas Alexander, MDMPH, Amit Budraja, PhD, Stanley Pounds, PhD, Kristin E Canavera, PhD, Lei Wang, MS, Joshua Wolf, MBBS, PhD, Jeffery M. Klco, MD PhD, Ahmed Hamed Salem, PhD FCP, Tammy Palenski, PhD, Norman J. Lacayo, MD, Ching-Hon Pui, MD, Joseph T. Opferman, PhD, Jeffrey Rubnitz, MD PhD

Blood (2019) 134 (Supplement_1): 178.

https://doi.org/10.1182/blood-2019-127716

Published: 2019

Journal Articles

A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Iman Aboudalle, MD, Marina Y Konopleva, MD PhD, Tapan M. Kadia, MD, Kiran Naqvi, MDMPH, Kenneth Vaughan, RN, Mehmet Kurt, RN, Antonio Cavazos, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Lucia Masarova, MD, Musa E. Yilmaz, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Steven M. Kornblau, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 176.

https://doi.org/10.1182/blood-2019-121780

Published: 2019

Journal Articles

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Jessica K. Altman, Tsila Zuckerman, MD, Olga Frankfurt, MD, Selina M. Luger, MD FRCPC, Dale L. Bixby, MD, Vamsi Kota, MBBS, Micah M. Burch, Ofir Wolach, Itai Levi, MD, Anna Gourevitch, Ron Ram, MD, Liat Flaishon, Shoshi Tessler, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe, MB, BS

Blood (2019) 134 (Supplement_1): 179.

https://doi.org/10.1182/blood-2019-124330

Published: 2019

Journal Articles

Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation

Kalyan Nadiminti, M Hasib Sidiqi, MBBS, Kapil Meleveedu, MDMBBS, Hassan B. Alkhateeb, MD, Aref Al-Kali, MD, William J Hogan, MB, BCh, Mark Litzow, MD, Shaji K. Kumar, MD, Mrinal M Patnaik, MDMBBS, Morie A. Gertz, MD, Dong Chen, MD PhD, Mithun Vinod Shah, MD PhD

Blood (2019) 134 (Supplement_1): 4560.

https://doi.org/10.1182/blood-2019-123065

Published: 2019

Journal Articles

Exceptional Responders to Hypomethylating Agents in Myeloid Neoplasms: The Miami Experience

Venkata Thammineni, MD, Terrence J Bradley, MD, Felipe Novoa, NP, Deukwoo Kwon, Justin M. Watts, MD

Blood (2019) 134 (Supplement_1): 5107.

https://doi.org/10.1182/blood-2019-131006

Published: 2019

Journal Articles

Association of Nucleophosmin-1 (NPM1) Expression with Leucocyte Count, Blast Count, and Gingiva Hypertrophy in Acute Myeloid Leukemia De Novo Patients in General Hospital of Dr M Djamil Padang Indonesia

Irza Wahid, MD PhD, Tubagus Djumhana Atmakusuma, MD PhD

Blood (2019) 134 (Supplement_1): 5171.

https://doi.org/10.1182/blood-2019-125950

Published: 2019

Journal Articles

Venetoclax and Cytarabine in AML Transformed from Myelofibrosis

John McKay, DO, Matthew Gayhart, MD, Taha Al-Juhaishi, MD, Victor Yazbeck, MD, Edward B. Perkins, MD PhD

Blood (2019) 134 (Supplement_1): 5140.

https://doi.org/10.1182/blood-2019-129429

Published: 2019

Journal Articles

Encouraging Results with ALL IC-BFM 2009 Protocol Therapy in Pediatric Acute Lymphoblastic Leukemia/Lymphoma in Resource-Limited Setting: A Single-Center Study from India

Uttam Kumar Nath, MDDM, Debranjani Chattopadhyay, MD, Anamika Bakliwal, MD, Sudeep Vaniyath, MD, Rituparna Chetia, MD, Ashok K Rajoreya, MD

Blood (2019) 134 (Supplement_1): 5118.

https://doi.org/10.1182/blood-2019-127985

Published: 2019

Journal Articles

Epichaperome Abundance Predicts Response to the Epichaperome Inhibitor, Puh-71, in Acute Myeloid Leukemia

Montreh Tavakkoli, MA,MD, Justin D. Kaner, MD, Sharma Sahil, PhD, Tony Taldone, PhD, Swathi Merugu, PhD, Gabriela Chiosis, PhD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 5145.

https://doi.org/10.1182/blood-2019-125175

Published: 2019

NARROW

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML

A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Acute Myeloid Leukemia (AML) in a 3D Bone Marrow Niche Showed High Performance for in Vitro and In Vivo Drug Screenings

Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy

Transient Switch to Myeloid Lineage in Acute Lymphoblastic Leukemia during Induction Therapy: The Role of CD371 Expression and Implication for Minimal Residual Disease Detection

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia

A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation

Exceptional Responders to Hypomethylating Agents in Myeloid Neoplasms: The Miami Experience

Association of Nucleophosmin-1 (NPM1) Expression with Leucocyte Count, Blast Count, and Gingiva Hypertrophy in Acute Myeloid Leukemia De Novo Patients in General Hospital of Dr M Djamil Padang Indonesia

Venetoclax and Cytarabine in AML Transformed from Myelofibrosis

Encouraging Results with ALL IC-BFM 2009 Protocol Therapy in Pediatric Acute Lymphoblastic Leukemia/Lymphoma in Resource-Limited Setting: A Single-Center Study from India

Epichaperome Abundance Predicts Response to the Epichaperome Inhibitor, Puh-71, in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only